Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Operating Expenses: 2015-2025

Historic Operating Expenses for Spyre Therapeutics (SYRE) over the last 11 years, with Sep 2025 value amounting to $56.9 million.

  • Spyre Therapeutics' Operating Expenses rose 2.70% to $56.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $213.6 million, marking a year-over-year increase of 10.57%. This contributed to the annual value of $208.6 million for FY2024, which is 14.24% down from last year.
  • Per Spyre Therapeutics' latest filing, its Operating Expenses stood at $56.9 million for Q3 2025, which was up 35.66% from $41.9 million recorded in Q2 2025.
  • In the past 5 years, Spyre Therapeutics' Operating Expenses ranged from a high of $159.9 million in Q2 2023 and a low of $18.2 million during Q1 2021.
  • Moreover, its 3-year median value for Operating Expenses was $47.8 million (2024), whereas its average is $54.9 million.
  • Per our database at Business Quant, Spyre Therapeutics' Operating Expenses spiked by 593.92% in 2023 and then crashed by 72.40% in 2024.
  • Spyre Therapeutics' Operating Expenses (Quarterly) stood at $24.1 million in 2021, then fell by 19.75% to $19.3 million in 2022, then soared by 137.53% to $45.9 million in 2023, then surged by 33.41% to $61.3 million in 2024, then climbed by 2.70% to $56.9 million in 2025.
  • Its Operating Expenses stands at $56.9 million for Q3 2025, versus $41.9 million for Q2 2025 and $53.6 million for Q1 2025.